Skip to main content
. 2012 Apr;97(4):560–567. doi: 10.3324/haematol.2011.053058

Table 2.

Invasive fungal diseases in patients with AML during front-line chemotherapy: comparison of patients who received oral amphotericin B primary antifungal prophylaxis (control group) with patients who received oral posaconazole primary antifungal prophylaxis (posaconazole group).

graphic file with name 97560.tab2.jpg